Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Average Price Target from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $56.33.

Several research firms have weighed in on AGIO. Scotiabank upped their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Raymond James reissued an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Royal Bank of Canada raised their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $60.00 to $56.00 in a report on Friday, September 27th.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $35.12 on Friday. The stock’s 50-day moving average is $47.15 and its two-hundred day moving average is $45.63. The stock has a market cap of $2.00 billion, a PE ratio of 3.09 and a beta of 0.87. Agios Pharmaceuticals has a fifty-two week low of $20.96 and a fifty-two week high of $62.58.

Insider Buying and Selling

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds have recently bought and sold shares of AGIO. Erste Asset Management GmbH acquired a new position in shares of Agios Pharmaceuticals during the third quarter valued at about $97,199,000. Marshall Wace LLP increased its stake in Agios Pharmaceuticals by 307.8% during the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after acquiring an additional 855,739 shares during the period. Vestal Point Capital LP acquired a new position in Agios Pharmaceuticals in the 3rd quarter valued at approximately $33,767,000. Frazier Life Sciences Management L.P. lifted its position in shares of Agios Pharmaceuticals by 66.7% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock worth $37,600,000 after acquiring an additional 348,808 shares during the period. Finally, Candriam S.C.A. acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $13,922,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.